Table 3.

Immunogenicity of BNT162b2 vaccine

	First-dose immunogenicity at week 3 (95% CI)	Immunogenicity at week 5 (95% CI)
		No boost	Day 21 boost
Anti-SARS-CoV-2 IgG response
Health-care workers	32/34; 94% (81–98)	18/21; 86% (65–95)	12/12; 100% (76–100)
Solid cancer cohort	21/56; 38% (26–51)	10/33; 30% (17–47)	18/19; 95% (75–99)
Haematological cancer cohort	8/44; 18% (10–32)	4/36; 11% (4–25)	3/5*; 60% (23–88)
T-cell vaccine response
Health-care workers	14/17; 82% (59–94)	9/13; 69% (42–87)	3/3*; 100% (44–100)
Solid cancer cohort	22/31; 71% (53–84)	8/15; 53% (30–75)	14/16; 88% (64–97)
Haematological cancer cohort	9/18; 50% (29–71)	6/18; 33% (16–56)	3/4*; 75% (40–95)

Data are n/N; % (95% CI). 95% CIs were calculated by the Wilson method.

^*Insufficient numbers for clinical interpretation.